GF/B22/DP10
Approved by the Board on: 15 December 2010
Quality Assurance Policy for diagnostic products
The Board approves the quality assurance policy for diagnostic products ("QA Policy for Diagnostics"), as set out in Annex 2 to the Report of the Market Dynamics and Commodities Ad-hoc Committee to the Board (GF/B22/11, Revision 1).
The Board requests the Secretariat to work with the World Health Organisation (WHO) towards concluding an agreement under which WHO will manage the technical evaluation of diagnostic products, including, as relevant, the establishment of an Expert Review Panel for Diagnostics, as described in the QA Policy for Diagnostics.
The Board further requests the Secretariat to work with WHO to explore measures to ensure principal recipients procure appropriately performing malaria rapid diagnostic tests (RDTs) and the MDC to report back by the Twenty-Fourth Board Meeting.
Budgetary Implications
The incremental budgetary implications of this decision point for the 2011 Operating Expenses Budget amount to US$ 675,000 to support the provision of technical services for the testing framework. This amount is not included in the proposed 2011 Operating Expenses Budget.